Kang Stem Biotech Co., Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Seoul Korea, Republic of (2010)

Organization Overview

First Clinical Trial
2013
NCT01927705
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Kang Stem Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

umbilical cord mesenchymal stem cells (8 trials)

Drugs in Phase 2 Trials (1)

stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Crohn Disease (Phase 2)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Eczema (Phase 3)

Psoriasis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 2